‘Inherently implausible’: Generic Partners loses fight with Neurim over melatonin drug patent

David Larish 2022-01-20 2:59 pm By Cindy Cameronne | Sydney

Please login to bookmark

Israeli drug company Neurim Pharmaceuticals has won an eight month extension to apply for a grace period for its melatonin tablet patent to treat children with autism spectrum disorder after Australian company Generic Partners lost its “inherently implausible” opposition to the patent.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au